Vortioxetine (Brintellix): A New Serotonergic Antidepressant

Authors

Mario A. D'Agostino, Nova Southeastern UniversityFollow
Clayton English, Nova Southeastern University
Jose A. Rey, Nova Southeastern UniversityFollow

Publication Title

P&T (Pharmacy & Therapeutics)

Volume

40

Issue

1

Publication Date / Copyright Date

1-1-2015

First Page

36

Last Page

40

Publisher

MediMedia

Abstract

Major depressive disorder (MDD) is a medical illness that affects how people feel, think, and behave, causing persistent feelings of sadness and loss of interest in previously enjoyed activity.1 Major depression frequently goes unrecognized and untreated and may foster tragic consequences, such as suicide and impaired interpersonal relationships at work and at home.1–3 Some people may experience only a single episode in their lifetimes, but more often a person may have multiple episodes.1–3 MDD is one of the most common mental disorders in the United States, affecting 6.7% of the population annually. Women are 70% more likely to experience MDD than men.2

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Keywords

antidepressant, major depressive disorder (MDD), pharmacotherapy, Vortioxetine (Brintellix)

NSUWorks Citation

D'Agostino, Mario A.; English, Clayton; and Rey, Jose A., "Vortioxetine (Brintellix): A New Serotonergic Antidepressant" (2015). Faculty Articles. 330.
https://nsuworks.nova.edu/hpd_corx_facarticles/330